TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Healios KK ( (JP:4593) ) has shared an announcement.
Healios K.K. has released its financial results for the third quarter of fiscal year 2025. The announcement provides insights into the company’s current financial standing and strategic direction, which could impact its operations and market position in the regenerative medicine sector. Stakeholders should consider the potential implications of these results on future company performance.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. is a company operating in the regenerative medicine industry, focusing on the development of innovative medical products. Their primary focus is on creating therapies that utilize stem cell technology to address various medical conditions.
Average Trading Volume: 3,579,896
Technical Sentiment Signal: Hold
Current Market Cap: Yen53.45B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.